Document:

Exhibit 10.10

 

Restricted Stock Award Agreement

 

This Restricted Stock Award Agreement
(this “Agreement”) is made and entered into as of [DATE] (the “Grant Date”) by and between
Tattooed Chef, Inc., a Delaware corporation (the “Company”), and ________________ (the “Grantee”).

 

WHEREAS, the Company has adopted
the Tattooed Chef, Inc. 2020 Incentive Award Plan (the “Plan”) pursuant to which awards of Restricted Stock
may be granted; and

 

WHEREAS, the Committee has determined
that it is in the best interests of the Company and its stockholders to grant the award of Restricted Stock provided for herein.

 

NOW, THEREFORE, the parties hereto, intending
to be legally bound, agree as follows:

 

1.
Grant of Restricted Stock. Pursuant to Section 9 of the Plan, the Company hereby issues to the Grantee on the Grant
Date a Restricted Stock Award consisting of, in the aggregate, [NUMBER] of Common Shares of the Company (the “Restricted
Stock”), on the terms and conditions and subject to the restrictions set forth in this Agreement and the Plan. Capitalized
terms that are used but not defined herein have the meaning ascribed to them in the Plan.

 

2.
Consideration. The grant of the Restricted Stock is made in consideration of the services to be rendered by the
Grantee to the Company.

 

3.
Restricted Period; Vesting.

 

3.1 Except
as otherwise provided herein, provided that the Grantee remains in Continuous Service through the applicable vesting date, the
Restricted Stock will vest in accordance with the following schedule:

 

	Vesting Date	Common Shares
	 	 
	[VESTING DATE]	[NUMBER OR PERCENTAGE OF SHARES THAT VEST ON THE VESTING DATE]
	 	 
	[VESTING DATE]	[NUMBER OR PERCENTAGE OF SHARES THAT VEST ON THE VESTING DATE]

 

The period over which the Restricted Stock
vests is referred to as the “Restricted Period”. As used in this Agreement, “Continuous Service”
means that the Grantee’s service with the Company or an Affiliate, whether as an employee, consultant or director, is not
interrupted or terminated. The Grantee’s Continuous Service shall not be deemed to have terminated merely because of a change
in the capacity in which the Grantee renders service to the Company or an Affiliate as an employee, consultant or director or
a change in the entity for which the Grantee renders such service, provided that there is no interruption or termination of the
Grantee’s Continuous Service; provided further that if any Award is subject to Section 409A of the Code, this sentence shall
only be given effect to the extent consistent with Section 409A of the Code. For example, a change in status from an employee
of the Company to a director of an Affiliate will not constitute an interruption of Continuous Service. The Committee or its delegate,
in its sole discretion, may determine whether Continuous Service will be considered interrupted in the case of any leave of absence
approved by that party, including sick leave, military leave or any other personal or family leave of absence. The Committee or
its delegate, in its sole discretion, may determine whether a Company transaction, such as a sale or spin-off of a division or
subsidiary that employs a Grantee, shall be deemed to result in a termination of Continuous Service for purposes of affected Awards,
and such decision shall be final, conclusive and binding.

 

     

     

    

 

3.2 The
foregoing vesting schedule notwithstanding, if the Grantee’s Continuous Service terminates for any reason at any time before
all of his or her Restricted Stock has vested, the Grantee’s unvested Restricted Stock shall be automatically forfeited
upon such termination of Continuous Service and neither the Company nor any Affiliate shall have any further obligations to the
Grantee under this Agreement.

 

3.3 Unless
otherwise determined by the Committee at the time of a Change in Control, a Change in Control shall have no effect on the Restricted
Stock.

 

4.
Restrictions. Subject to any exceptions set forth in this Agreement or the Plan, during the Restricted Period, the
Restricted Stock or the rights relating thereto may not be assigned, alienated, pledged, attached, sold or otherwise transferred
or encumbered by the Grantee. Any attempt to assign, alienate, pledge, attach, sell or otherwise transfer or encumber the Restricted
Stock or the rights relating thereto during the Restricted Period shall be wholly ineffective and, if any such attempt is made,
the Restricted Stock will be forfeited by the Grantee and all of the Grantee’s rights to such shares shall immediately terminate
without any payment or consideration by the Company.

 

5.
Rights as Stockholder; Dividends.

 

5.1 The
Grantee shall be the record owner of the Restricted Stock until the Common Shares are sold or otherwise disposed of, and shall
be entitled to all of the rights of a stockholder of the Company including, without limitation, the right to vote such shares
and receive all dividends or other distributions paid with respect to such shares. Notwithstanding the foregoing, any dividends
or other distributions shall be subject to the same restrictions on transferability as the shares of Restricted Stock with respect
to which they were paid.

 

5.2 The
Company may issue stock certificates or evidence the Grantee’s interest by using a restricted book entry account with the
Company’s transfer agent. Physical possession or custody of any stock certificates that are issued shall be retained by
the Company until the time as the Restricted Stock vests.

 

5.3 If the
Grantee forfeits any rights he or she has under this Agreement in accordance with Section 3, the Grantee shall, on the date of
such forfeiture, no longer have any rights as a stockholder with respect to the Restricted Stock and shall no longer be entitled
to vote or receive dividends on such shares.

 

6.
No Right to Continued Service. Neither the Plan nor this Agreement shall confer upon the Grantee any right to be
retained in any position as an employee, consultant or director of the Company or its Affiliates. Further, nothing in the Plan
or this Agreement shall be construed to limit the discretion of the Company or any of its Affiliates to terminate the Grantee’s
Continuous Service at any time, with or without Cause.

 

    2

     

    

 

7.
Adjustments. If any change is made to the outstanding Common Shares or the capital structure of the Company, if
required, the Common Shares shall be adjusted or terminated in any manner as contemplated by Section 12 of the Plan.

 

8.
Tax Liability and Withholding.

 

8.1 The
Grantee shall be required to pay to the Company, and the Company shall have the right to deduct from any compensation paid to
the Grantee pursuant to the Plan, the amount of any required withholding taxes in respect of the Restricted Stock and to take
all such other action as the Committee deems necessary to satisfy all obligations for the payment of such withholding taxes. The
Committee may permit the Grantee to satisfy any federal, state or local tax withholding obligation by any of the following means,
or by a combination of such means:

 

(a) tendering
a cash payment.

 

(b) authorizing
the Company to withhold Common Shares from those Common Shares that would otherwise be issuable or deliverable to the Grantee
as a result of the vesting of the Restricted Stock; provided, however, that no Common Shares shall be withheld with a value exceeding
the [minimum/maximum] amount of tax required to be withheld by law.

 

(c) delivering
to the Company previously owned and unencumbered Common Shares.

 

8.2 Notwithstanding
any action the Company takes with respect to any or all income tax, social insurance, payroll tax, or other tax-related withholding
(“Tax-Related Items”), the ultimate liability for all Tax-Related Items is and remains the Grantee’s
responsibility and the Company (a) makes no representation or undertakings regarding the treatment of any Tax-Related Items in
connection with the grant or vesting of the Restricted Stock or the subsequent sale of any shares; and (b) does not commit to
structure the Restricted Stock to reduce or eliminate the Grantee’s liability for Tax-Related Items.

 

9.
Section 83(b) Election. The Grantee may make an election under Code Section 83(b) (a “Section 83(b) Election”)
with respect to the Restricted Stock. Any such election must be made within thirty (30) days after the Grant Date. If the Grantee
elects to make a Section 83(b) Election, the Grantee shall provide the Company with a copy of an executed version and satisfactory
evidence of the filing of the executed Section 83(b) Election with the US Internal Revenue Service. The Grantee agrees to assume
full responsibility for ensuring that the Section 83(b) Election is actually and timely filed with the US Internal Revenue Service
and for all tax consequences resulting from the Section 83(b) Election.

 

    3

     

    

 

10.
[Non-competition and Non-solicitation.

 

10.1 In
consideration of the Restricted Stock, the Grantee agrees and covenants not to:

 

(a) contribute
his or her knowledge, directly or indirectly, in whole or in part, as an employee, officer, owner, manager, advisor, consultant,
agent, partner, director, stockholder, volunteer, intern or in any other similar capacity to an entity engaged in the same or
similar business as the Company and its Affiliates, including those engaged in the business of [producing and/or manufacturing
of plant-based frozen food] for a period of [___] following the Grantee’s termination of Continuous Service;

 

(b) directly
or indirectly, solicit, hire, recruit, attempt to hire or recruit, or induce the termination of employment of any employee of
the Company or its Affiliates for [___] following the Grantee’s termination of Continuous Service; or

 

(c) directly
or indirectly, solicit, contact (including, but not limited to, e-mail, regular mail, express mail, telephone, fax, and instant
message), attempt to contact or meet with the current[, former or prospective] customers of the Company or any of its Affiliates
for purposes of offering or accepting goods or services similar to or competitive with those offered by the Company or any of
its Affiliates for a period of [_____] following the Grantee’s termination of Continuous Service.

 

10.2 If
the Grantee breaches any of the covenants set forth in Section 10.1:

 

(a) all
unvested Restricted Stock shall be immediately forfeited; and

 

(b) the
Grantee hereby consents and agrees that the Company shall be entitled to seek, in addition to other available remedies, a temporary
or permanent injunction or other equitable relief against such breach or threatened breach from any court of competent jurisdiction,
without the necessity of showing any actual damages or that money damages would not afford an adequate remedy, and without the
necessity of posting any bond or other security. The aforementioned equitable relief shall be in addition to, not in lieu of,
legal remedies, monetary damages or other available forms of relief.]

 

11.
Compliance with Law. The issuance and transfer of Common Shares shall be subject to compliance by the Company and the
Grantee with all applicable requirements of federal and state securities laws and with all applicable requirements of any stock
exchange on which the Common Shares may be listed. No Common Shares shall be issued or transferred unless and until any then applicable
requirements of state and federal laws and regulatory agencies have been fully complied with to the satisfaction of the Company
and its counsel. The Grantee understands that the Company is under no obligation to register the Common Shares with the Securities
and Exchange Commission, any state securities commission or any stock exchange to effect such compliance.

 

    4

     

    

 

12.
Legends. A legend may be placed on any certificate(s) or other document(s) delivered to the Grantee and may be noted
in the book entry account with the Company’s transfer agent indicating restrictions on transferability of the shares of
Restricted Stock pursuant to this Agreement or any other restrictions that the Committee may deem advisable under the rules, regulations
and other requirements of the Securities and Exchange Commission, any applicable federal or state securities laws or any stock
exchange on which the Common Shares are then listed or quoted.

 

13.
Notices. Any notice required to be delivered to the Company under this Agreement shall be in writing and addressed
to the Chief Financial Officer of the Company at the Company’s principal corporate offices. Any notice required to be delivered
to the Grantee under this Agreement shall be in writing and addressed to the Grantee at the Grantee’s address as shown in
the records of the Company. Either party may designate another address in writing (or by such other method approved by the Company)
from time to time.

 

14.
Governing Law. This Agreement will be construed and interpreted in accordance with the laws of the State of Delaware
without regard to conflict of law principles.

 

15.
Interpretation. Any dispute regarding the interpretation of this Agreement shall be submitted by the Grantee or the
Company to the Committee for review. The resolution of such dispute by the Committee shall be final and binding on the Grantee
and the Company.

 

16.
Restricted Stock Subject to Plan. This Agreement is subject to the Plan as approved by the Company’s stockholders.
The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. In the
event of a conflict between any term or provision contained herein and a term or provision of the Plan, the applicable terms and
provisions of the Plan will govern and prevail.

 

17.
Successors and Assigns. The Company may assign any of its rights under this Agreement. This Agreement will be binding
upon and inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth
herein, this Agreement will be binding upon the Grantee and the Grantee’s beneficiaries, executors, administrators and the
person(s) to whom the Restricted Stock may be transferred by will or the laws of descent or distribution.

 

18.
Severability. The invalidity or unenforceability of any provision of the Plan or this Agreement shall not affect the
validity or enforceability of any other provision of the Plan or this Agreement, and each provision of the Plan and this Agreement
shall be severable and enforceable to the extent permitted by law.

 

    5

     

    

 

19.
Discretionary Nature of Plan. The Plan is discretionary and may be amended, cancelled or terminated by the Company
at any time, in its discretion. The grant of the Restricted Stock in this Agreement does not create any contractual right or other
right to receive any Restricted Stock or other Awards in the future. Future Awards, if any, will be at the sole discretion of
the Company. Any amendment, modification, or termination of the Plan shall not constitute a change or impairment of the terms
and conditions of the Grantee’s employment with the Company.

 

20.
Amendment. The Committee has the right to amend, alter, suspend, discontinue or cancel the Restricted Stock, prospectively
or retroactively; provided, that, no such amendment shall adversely affect the Grantee’s material rights under this Agreement
without the Grantee’s consent.

 

21.
No Impact on Other Benefits. The value of the Grantee’s Restricted Stock is not part of his or her normal or
expected compensation for purposes of calculating any severance, retirement, welfare, insurance or similar employee benefit.

 

22.
Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of
which together will constitute one and the same instrument. Counterpart signature pages to this Agreement transmitted by facsimile
transmission, by electronic mail in portable document format (.pdf), or by any other electronic means intended to preserve the
original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document
bearing an original signature.

 

23.
Acceptance. The Grantee hereby acknowledges receipt of a copy of the Plan and this Agreement. The Grantee has read
and understands the terms and provisions thereof, and accepts the Restricted Stock subject to all of the terms and conditions
of the Plan and this Agreement. The Grantee acknowledges that there may be adverse tax consequences upon the grant or vesting
of the Restricted Stock or disposition of the underlying shares and that the Grantee has been advised to consult a tax advisor
prior to such grant, vesting or disposition.

 

[signature page
follows]

 

    6

     

    

 

IN WITNESS WHEREOF, the parties hereto
have executed this Agreement as of the date first above written.

 

	 	Tattooed Chef, Inc.
	 	 
	 	By: _____________________
	 	Name:
	 	Title:
	 	 
	 	[EMPLOYEE NAME]
	 	 
	 	By:  _____________________
	 	Name:

 

 

[Signature Page to Restricted Stock Award
Agreement]EX-10.1

 Exhibit 10.1 

SUBSCRIPTION AGREEMENT 

March 19, 2021 
 SC Health Corporation 

108 Robinson Road #10-00 

Singapore 068900 
 Rockley Photonics Holdings Limited 

3rd Floor 1 Ashley Road 
 Altrincham, Cheshire 

United Kingdom, WA14 2DT 
 Ladies and Gentlemen: 

In connection with the proposed business combination (the “Transaction”) between SC Health Corporation, a Cayman Islands
exempted company (“SC Health”), and Rockley Photonics, Ltd., a company incorporated under the laws of England and Wales with company number 08683015 (“Target”), pursuant to that certain Business Combination
Agreement and Plan of Merger, dated as of March 19, 2021 (as it may be amended, the “Transaction Agreement”), by and among SC Health, Target, Rockley Photonics Holdings Limited, an exempted company incorporated in the Cayman
Islands with limited liability (“HoldCo”) and Rockley Mergersub Limited, an exempted company incorporated in the Cayman Islands with limited liability and a direct wholly owned subsidiary of HoldCo, SC Health is seeking commitments
to purchase ordinary shares (the “Ordinary Shares”), of HoldCo for a purchase price of $10.00 per share (the “Purchase Price”), in a private placement to be conducted by HoldCo and SC Health (the
“Offering”). In connection therewith, the undersigned subscriber (“Subscriber”), SC Health and HoldCo agree in this subscription agreement (this “Subscription Agreement”) as follows: 

1. Subscription. As of the date written above (the “Subscription Date”), the Subscriber hereby
irrevocably subscribes for and agrees to purchase from HoldCo such number of Ordinary Shares as is set forth on the signature page of this Subscription Agreement (the “Shares”) at the Purchase Price per Share and on the terms
provided for herein. 
 SC Health and HoldCo have entered into separate subscription agreements (the “Other Subscription
Agreements”) with certain other “qualified institutional buyers” (as defined in Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”)) or “accredited investors” (within the
meaning of Rule 501(a)(1), (2), (3), (7) or (8) under the Securities Act) (each, an “Other Subscriber”), pursuant to which such investors have agreed to purchase Ordinary Shares on the Closing Date and the aggregate gross
proceeds from the securities to be sold by HoldCo pursuant to this Subscription Agreement and the Other Subscription Agreements equals, as of the date hereof, $150,000,000. 

2. Closing; Delivery of Shares. 

(a) The closing of the sale of Shares contemplated hereby (the “Closing”, and the date that the Closing actually occurs, the
“Closing Date”) is contingent upon the substantially concurrent consummation of the Transaction (the “Transaction Closing”). The Closing shall occur on the date of the Transaction Closing, and immediately prior to,
the Merger Effective Time (as defined in the Transaction Agreement). 

 (b) HoldCo shall provide written notice (which may be via email) to the Subscriber (the
“Closing Notice”) that HoldCo reasonably expects the Transaction Closing to occur on a date specified in the notice (the “Scheduled Closing Date”) that is not less than three (3) business days from the date of
the Subscriber’s receipt of the Closing Notice, which Closing Notice shall contain HoldCo’s wire instructions for an escrow account (the “Escrow Account”) established by HoldCo with a third party escrow agent (the
“Escrow Agent”) to be identified in the Closing Notice. At least two (2) business days prior to the Scheduled Closing Date, the Subscriber shall deliver to the Escrow Account the aggregate Purchase Price for the Shares
subscribed by wire transfer of United States dollars in immediately available funds. Upon the Closing, HoldCo shall provide instructions to the Escrow Agent to release the funds in the Escrow Account to HoldCo against delivery to the Subscriber of
the Shares, free and clear of any liens or other restrictions whatsoever (other than those arising under state or federal securities laws), in book-entry form as set forth in Section 2(c) below. If this Subscription
Agreement is terminated prior to the Closing and any funds have already been sent by the Subscriber to the Escrow Account, then promptly (but in no event later than five (5) business days after the Scheduled Closing Date specified in the
Closing Notice) after such termination, HoldCo will instruct the Escrow Agent to promptly return such funds to the Subscriber. 
 (c) On the
Closing Date, promptly after the Closing, HoldCo shall deliver (or cause the delivery of) the Shares in book-entry form with restrictive legends in the amount as set forth on the signature page to the Subscriber as indicated on the signature page.

 3. Closing Conditions. In addition to the condition set forth in the first sentence of Section 2(a) above: 

(a) The Closing is also subject to the satisfaction or valid waiver by each party to this Subscription Agreement of the conditions that, on the
Closing Date: 
 (i) no suspension of the qualification of the Shares for offering or sale or trading in any jurisdiction, or initiation or
threatening of any proceedings for any of such purposes, shall have occurred; 
 (ii) no governmental authority of competent jurisdiction
shall have rendered, issued, promulgated, enforced or entered any judgment, order, law, rule or regulation (whether temporary, preliminary or permanent) which is then in effect and which then makes the consummation of the transactions contemplated
hereby illegal or then restrains or prohibits the consummation of the transactions contemplated hereby; and 
 (iii) all material conditions
precedent to the Transaction Closing set forth in the Transaction Agreement shall have been satisfied or waived (other than those conditions which, by their nature, are to be satisfied at the Transaction Closing). 

(b) The obligations of SC Health and HoldCo to consummate the Closing are also subject to the satisfaction or valid waiver by SC Health and
HoldCo of the additional conditions that, on the Closing Date: 
 (i) all representations and warranties of the Subscriber contained in this
Subscription Agreement shall be true and correct in all material respects at and as of the Closing Date (except for representations and warranties made as of a specific date, which shall be true and correct in all material respects as of such date);
and 
 (ii) the Subscriber shall have performed, satisfied and complied in all material respects with all covenants, agreements and
conditions required by this Subscription Agreement to be performed, satisfied or complied with by it at or prior to Closing. 

  
 2 

 (c) The obligations of the Subscriber to consummate the Closing are also subject to the
satisfaction or valid waiver by the Subscriber of the additional conditions that, on the Closing Date: 
 (i) all representations and
warranties of SC Health and HoldCo contained in this Subscription Agreement shall be true and correct in all material respects (other than representations and warranties that are qualified as to materiality or Material Adverse Effect (as defined
herein), which representations and warranties shall be true in all respects) at and as of the Closing Date (except for representations and warranties made as of a specific date, which shall be true and correct in all material respects (other than
representations and warranties that are qualified as to materiality or Material Adverse Effect, which representations and warranties shall be true in all respects) as of such date); 

(ii) SC Health and HoldCo shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions
required by this Subscription Agreement to be performed, satisfied or complied with by it at or prior to Closing; and 
 (iii) no amendment,
modification or waiver of the Transaction Agreement shall have occurred that reasonably would be expected to materially and adversely affect the economic benefits that the Subscriber reasonably would expect to receive under this Subscription
Agreement. 
 4. SC Health and HoldCo Representations and Warranties. Each of SC Health (other than in respect of
paragraph (b) below) and HoldCo represents and warrants to the Subscriber severally (and not jointly and severally), as to itself only, that: 

(a) As of the date hereof, each of SC Health and HoldCo is an exempted company duly organized, validly existing and in good standing under the
laws of the Cayman Islands. Immediately following the Transaction Closing under the Transaction Agreement, each of SC Health and HoldCo will be validly existing and in good standing under the laws of its jurisdiction of organization. Each of SC
Health and HoldCo has the corporate power and authority to own, lease and operate its respective properties and conduct its respective business as presently conducted and to enter into, deliver and perform its obligations under this Subscription
Agreement. 
 (b) All issued and outstanding Ordinary Shares have been duly authorized and validly issued, are fully paid and are non-assessable and are not subject to pre-emptive rights. The Shares have been duly authorized and, when issued and delivered to the Subscriber against full payment therefor
in accordance with the terms of this Subscription Agreement, the Shares will be validly issued, fully paid and non-assessable and will not have been issued in violation of or subject to any preemptive or
similar rights created under HoldCo’s Articles of Association or under the laws of the Cayman Islands. 
 (c) This Subscription
Agreement has been duly authorized, executed and delivered by each of SC Health and HoldCo and is enforceable against each of SC Health and HoldCo in accordance with its terms, except as may be limited or otherwise affected by (i) bankruptcy,
insolvency, fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting the rights of creditors generally, and (ii) principles of equity, whether considered at law or equity. 

(d) The issuance and sale of the Shares by HoldCo and the compliance by each of SC Health and HoldCo with all of the provisions of this
Subscription Agreement and the consummation of the transactions herein will be done in accordance with the NYSE listing rules and will not conflict with or result in a material breach or material violation of any of the terms or provisions of, or
constitute a material default under, or result in the creation or imposition of any lien, charge or encumbrance upon any of the property or assets of SC Health or HoldCo or any of their respective subsidiaries pursuant to the terms of (i) any
indenture, mortgage, deed of trust, loan agreement, license, lease or any other agreement or 

  
 3 

 
instrument to which SC Health or HoldCo or any of their respective subsidiaries is a party or by which SC Health or HoldCo or any of their respective subsidiaries is bound or to which any of the
property or assets of SC Health or HoldCo is subject, which would have a material adverse effect on the business, properties, financial condition, stockholders’ equity or results of operations of SC Health or HoldCo (a “Material Adverse
Effect”) or materially affect the validity of the Shares or the legal authority of SC Health or HoldCo to comply in all material respects with the terms of this Subscription Agreement; (ii) result in any material violation of the
provisions of the organizational documents of SC Health or HoldCo; or (iii) result in any violation of any statute or any judgment, order, rule or regulation of any court or governmental agency or body, domestic or foreign, having jurisdiction
over SC Health or HoldCo or any of its properties that would have a Material Adverse Effect or materially affect the validity of the Shares or the legal authority of SC Health or HoldCo to comply with this Subscription Agreement; subject, in the
case of the foregoing clauses (i) and (iii) with respect to the consummation of the transactions therein contemplated. 
 (e) Neither SC
Health nor HoldCo has entered into any agreement or arrangement entitling any agent, broker, investment banker, financial advisor or other person to any broker’s or finder’s fee or any other commission or similar fee in connection with the
transactions contemplated by this Subscription Agreement for which the Subscriber could become liable. Other than Merrill Lynch (Singapore) Pte. Ltd. (and its affiliates) and Cowen and Company, LLC. (collectively, the “Placement
Agents”), neither SC Health nor HoldCo is aware of any person that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale of any shares of Ordinary Shares in the Offering.

 (f) HoldCo is not, and immediately after receipt of payment for the Shares, will not be, an “investment company” within the
meaning of the Investment Company Act of 1940, as amended. 
 (g) Assuming the accuracy of the Subscriber’s representations and
warranties set forth in Section 5, in connection with the offer, sale and delivery of the Shares in the manner contemplated by this Subscription Agreement, it is not necessary to register the Shares under the Securities
Act. 
 (h) Neither SC Health, HoldCo, nor any person acting on their behalf has, directly or indirectly, made any offers or sales of any
HoldCo security or solicited any offers to buy any security under circumstances that would adversely affect reliance by HoldCo on either Regulation S under the Securities Act or Section 4(a)(2) of the Securities Act for the exemption from
registration for the transactions contemplated hereby or would require registration of the issuance of the Shares under the Securities Act. 

(i) There are no Other Subscription Agreements, side letter agreements or other agreements or understandings (including written summaries of
any oral understandings) with any Other Subscriber that include terms and conditions that are materially more advantageous to any such Other Subscriber (as compared to Subscriber) containing any of the following: (i) any rights or benefits
granted to an Other Subscriber in connection with such Other Subscriber’s compliance with any law, regulation or policy specifically applicable to such Other Subscriber or in connection with the taxable status of an Other Subscriber,
(ii) any rights or benefits which are personal to an Other Subscriber based solely on its place of organization or headquarters, organizational form of, or other particular restrictions applicable to, such Other Subscriber, or (iii) any
rights with respect to the confidentiality or disclosure of an Other Subscriber’s identity, and such Other Subscription Agreements, other agreements and understandings, as applicable, have not been amended in any material respect following the
date of this Subscription Agreement and reflect the same Per Share Purchase Price and terms that are not more favorable in any material respect to such Other Subscriber thereunder than the terms of this Subscription Agreement. 

  
 4 

 (j) SC Health has made available to Subscriber (including via the SEC’s EDGAR system) a
true, correct and complete copy of each form, report, statement, schedule, prospectus, proxy, registration statement and other documents filed by SC Health with the SEC prior to the date of this Subscription Agreement (the “SEC
Documents”). None of the SEC Documents filed under the Exchange Act, contained, when filed or, if amended prior to the date of this Subscription Agreement, as of the date of such amendment with respect to those disclosures that are
amended, any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. SC Health has
timely filed each report, statement, schedule, prospectus, and registration statement that SC Health was required to file with the SEC since its inception and through the date hereof. There are no material outstanding or unresolved comments in
comment letters from the SEC staff with respect to any of the SEC Documents. 
 (k) Each of HoldCo and SC Health understands that the
foregoing representations and warranties shall be deemed material to and have been relied upon by the Subscriber. 
 5.
Subscriber Representations, Warranties and Covenants. The Subscriber represents and warrants to SC Health and HoldCo that: 

(a) At the time the Subscriber was offered the Shares, it was, and as of the date hereof, the Subscriber is (i) (A) a “qualified
institutional buyer” (as defined in Rule 144A under the Securities Act) or an “accredited investor” (within the meaning of Rule 501(a)(1), (2), (3), (7) or (8) under the Securities Act) satisfying the applicable requirements as
set forth on Schedule I, (B) an “Institutional Account” as such term is defined in FINRA Rule 4512(c), (C) acquiring the Shares only for its own account and (D) not acquiring the Shares for the account of others, and not
on behalf of any other account or person or with a view to, or for offer or sale in connection with, any distribution thereof in violation of the Securities Act or (ii) is not a “U.S. person” within the meaning of Regulation S under
the Securities Act. The Subscriber is not an entity formed for the specific purpose of acquiring the Shares. 
 (b) The Subscriber
understands that the Shares are being offered in a transaction not involving any public offering within the meaning of the Securities Act and that the Shares delivered at the Closing have not been registered under the Securities Act. The Subscriber
understands that the Shares may not be resold, transferred, pledged or otherwise disposed of by the Subscriber absent an effective registration statement under the Securities Act except (i) to HoldCo or a subsidiary thereof, (ii) to non-U.S. persons pursuant to offers and sales that occur outside the United States within the meaning of Regulation S under the Securities Act or (iii) pursuant to another applicable exemption from the
registration requirements of the Securities Act, and in accordance with applicable securities laws of the states and other jurisdictions, and that any certificates (if any) or any book-entry shares representing the Shares delivered at the Closing
shall contain a legend or restrictive notation to such effect. The Subscriber understands and agrees that the Shares, until registered under an effective registration statement, will be subject to transfer restrictions and, as a result of these
transfer restrictions, the Subscriber may not be able to readily resell the Shares and may be required to bear the financial risk of an investment in the Shares for an indefinite period of time. The Subscriber understands that it has been advised to
consult legal counsel prior to making any offer, resale, pledge or transfer of any of the Shares. 
 (c) The Subscriber understands and
agrees that the Subscriber is purchasing Shares directly from HoldCo. The Subscriber further acknowledges that there have been no representations, warranties, covenants and agreements made to the Subscriber by SC Health or HoldCo, or any of its
officers or directors, expressly (other than those representations, warranties, covenants and agreements included in this Subscription Agreement) or by implication. 

(d) The Subscriber’s acquisition and holding of the Shares will not constitute or result in a
non-exempt prohibited transaction under Section 406 of the Employee Retirement Income Security Act of 1974, as amended, Section 4975 of the Internal Revenue Code of 1986, as amended, or any
applicable similar law. 

  
 5 

 (e) The Subscriber acknowledges and agrees that the Subscriber has received such information
as the Subscriber deems necessary in order to make an investment decision with respect to the Shares. Without limiting the generality of the foregoing, the Subscriber acknowledges that it has received and carefully reviewed the following items
(collectively, the “Disclosure Documents”): (i) the final prospectus of SC Health, dated as of July 11, 2019 and filed with the U.S. Securities and Exchange Commission (the “SEC”) (File No. 333-232240) on July 12, 2019 (the “Prospectus”), (ii) each filing made by SC Health with the SEC following the filing of the Prospectus through the date of this Subscription Agreement,
(iii) the Transaction Agreement, a copy of which will be filed by HoldCo and SC Health with the SEC and (iv) the investor presentation by SC Health and the Target, a copy of which will be furnished by HoldCo and SC Health to the SEC. The
undersigned understands the significant extent to which certain of the disclosures contained in items (i) and (ii) above shall not apply following the Transaction Closing. The Subscriber represents and agrees that the Subscriber and the
Subscriber’s professional advisor(s), if any, have had the full opportunity to ask SC Health’s and the Target’s management questions, receive such answers and obtain such information as the Subscriber and such Subscriber’s
professional advisor(s), if any, have deemed necessary to make an investment decision with respect to the Shares. The Subscriber has conducted its own investigation of SC Health, HoldCo, the Target and the Shares and the Subscriber has made its own
assessment and has satisfied itself concerning the relevant tax and other economic considerations relevant to its investment in the Shares. 

(f) The Subscriber became aware of this Offering of the Shares solely by means of direct contact between the Subscriber and SC Health, HoldCo,
the Placement Agents or a representative of SC Health, HoldCo or the Placement Agents, and the Shares were offered to the Subscriber solely by direct contact between the Subscriber and SC Health, HoldCo, the Placement Agents or a representative of
SC Health, HoldCo or the Placement Agents. The Subscriber acknowledges that SC Health and HoldCo each represents and warrants severally (and not jointly and severally), as to itself only, that the Shares (i) were not offered by any form of
general solicitation or general advertising and (ii) are not being offered in a manner involving a public offering under, or in a distribution in violation of, the Securities Act, or any state securities laws. Neither the Subscriber, nor any of
its directors, officers, employees, agents, stockholders or partners has either directly or indirectly, including through a broker or finder, (i) to its knowledge, engaged in any general solicitation, or (ii) published any advertisement in
connection with the Offering. 
 (g) The Subscriber acknowledges that it is aware that there are substantial risks incident to the purchase
and ownership of the Shares, including those set forth in the Disclosure Documents and in SC Health’s filings with the SEC. The Subscriber is able to fend for itself in the transactions contemplated herein and has such knowledge and experience
in financial and business matters as to be capable of evaluating the merits and risks of an investment in the Shares, and the Subscriber has sought such accounting, legal and tax advice as the Subscriber has considered necessary to make an informed
investment decision. 
 (h) Alone, or together with any professional advisor(s), the Subscriber has adequately analyzed and fully considered
the risks of an investment in the Shares and determined that the Shares are a suitable investment for the Subscriber and that the Subscriber is able at this time and in the foreseeable future to bear the economic risk of a total loss of the
Subscriber’s investment in HoldCo. The Subscriber acknowledges specifically that a possibility of total loss exists. 
 (i) In making
its decision to purchase the Shares, the Subscriber has relied solely upon independent investigation made by the Subscriber and the representations and warranties of SC Health and HoldCo set forth herein. Without limiting the generality of the
foregoing, the Subscriber has not relied on any statements or other information provided by the Placement Agents concerning SC Health, HoldCo, Target or the Shares or the offer and sale of the Shares. 

  
 6 

 (j) The Subscriber understands and agrees that no federal or state agency has passed upon or
endorsed the merits of this Offering of the Shares or made any findings or determination as to the fairness of this investment or the accuracy or adequacy of SC Health’s filings with the SEC. 

(k) The Subscriber has been duly formed or incorporated and is validly existing in good standing under the laws of its jurisdiction of
incorporation or formation. 
 (l) The execution, delivery and performance by the Subscriber of this Subscription Agreement are within the
powers of the Subscriber, have been duly authorized and will not constitute or result in a breach or default under or conflict with any federal or state statute, rule or regulation applicable to the Subscriber, any order, ruling or regulation of any
court or other tribunal or of any governmental commission or agency, or any agreement or other undertaking, to which the Subscriber is a party or by which the Subscriber is bound, and, if the Subscriber is not an individual, will not violate any
provisions of the Subscriber’s charter documents, including its incorporation or formation papers, bylaws, indenture of trust or partnership or operating agreement, as may be applicable. The signature on this Subscription Agreement is genuine,
and the signatory, if the Subscriber is an individual, has legal competence and capacity to execute the same or, if the Subscriber is not an individual the signatory has been duly authorized to execute the same, and this Subscription Agreement
constitutes a legal, valid and binding obligation of the Subscriber, enforceable against the Subscriber in accordance with its terms. 
 (m)
Neither the due diligence investigation conducted by the Subscriber in connection with making its decision to acquire the Shares nor any representations and warranties made by the Subscriber herein shall modify, amend or affect the Subscriber’s
right to rely on the truth, accuracy and completeness of SC Health’s and HoldCo’s representations and warranties contained herein. 

(n) The Subscriber is not (i) a person or entity named on the List of Specially Designated Nationals and Blocked Persons administered by
the U.S. Treasury Department’s Office of Foreign Assets Control (“OFAC”) or in any Executive Order issued by the President of the United States and administered by OFAC (“OFAC List”), or a person or entity
prohibited by any OFAC sanctions program, (ii) a Designated National as defined in the Cuban Assets Control Regulations, 31 C.F.R. Part 515, or (iii) a non-U.S. shell bank or providing banking
services indirectly to a non-U.S. shell bank (collectively, a “Prohibited Investor”). The Subscriber agrees to provide law enforcement agencies, if requested thereby, such records as required
by applicable law, provided that the Subscriber is permitted to do so under applicable law. If the Subscriber is a financial institution subject to the Bank Secrecy Act (31 U.S.C. Section 5311 et seq.), as amended by the USA PATRIOT Act of
2001, and its implementing regulations (collectively, the “BSA/PATRIOT Act”), the Subscriber maintains policies and procedures reasonably designed to comply with applicable obligations under the BSA/PATRIOT Act. To the extent
required, it maintains policies and procedures reasonably designed for the screening of its investors against the OFAC sanctions programs, including the OFAC List. To the extent required, it maintains policies and procedures reasonably designed to
ensure that the funds held by the Subscriber and used to purchase the Shares were legally derived. 
 (o) As of the date hereof and at the
Closing, neither the Subscriber, nor, to the extent it has them, any of its direct beneficial owners or (only so far as the Subscriber is aware) its indirect beneficial owners or its directors, affiliates or executive officers (collectively with the
Subscriber, the “Covered Persons”), are subject to any of the “Bad Actor” disqualifications described in Rule 506(d) under the Securities Act (a “Disqualification Event”), except for a Disqualification
Event covered by Rule 506(d)(2) or (d)(3). The Subscriber has exercised reasonable care to determine whether any Covered Person is subject to a Disqualification Event. The acquisition of Shares by the Subscriber will not subject SC Health or HoldCo
to any Disqualification Event. 

  
 7 

 (p) Subscriber is not currently (and at all times through Closing will refrain from being or
becoming) a member of a “group” (within the meaning of Section 13(d)(3) or Section 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or any successor provision), other than with those
persons or entities who may be deemed affiliates or control persons, acting for the purpose of acquiring, holding or disposing of or taking any other action relating to the equity securities of the Issuer (within the meaning of Rule 13d-5(b)(1) under the Exchange Act). 
 (q) No foreign person (as defined in 31 C.F.R. Part 800.224) in
which the national or subnational governments of a single foreign state have a substantial interest (as defined in 31 C.F.R. Part 800.244) will acquire a substantial interest in HoldCo as a result of the purchase and sale of Shares hereunder such
that a declaration to the Committee on Foreign Investment in the United States would be mandatory under 31 C.F.R. Part 800.401, and no foreign person will have control (as defined in 31 C.F.R. Part 800.208) over HoldCo from and after the Closing as
a result of the purchase and sale of Shares hereunder. 
 (r) No disclosure or offering document has been prepared by the Placement Agents in
connection with the offer and sale of the Shares. The Placement Agents and each of their respective members, directors, officers, employees, representatives and controlling persons have made no independent investigation with respect to HoldCo, SC
Health, the Target, any of their respective businesses, or the Shares or the accuracy, completeness or adequacy of any information supplied to the Subscriber by SC Health and/or HoldCo. In connection with the issue and purchase of the Shares, the
Placement Agents have not acted as the Subscriber’s financial advisor or fiduciary. 
 (s) The Subscriber acknowledges its obligations
under applicable securities laws with respect to the treatment of non-public information relating to SC Health and HoldCo. 

6. Registration Rights. HoldCo agrees that, within thirty (30) calendar days after the Transaction Closing, HoldCo
will file with the SEC (at HoldCo’s sole cost and expense) a registration statement registering the resale of the Shares (the “Registration Statement”), and HoldCo shall use its commercially reasonable efforts to have the
Registration Statement declared effective as soon as practicable after the filing thereof, but no later than the earlier of (i) ninety (90) calendar days after the filing thereof (or one hundred and twenty (120) calendar days after the
filing thereof in the event the SEC reviews and has written comments to the Registration Statement), and (ii) the tenth (10th) business day after the date HoldCo is notified in writing by the SEC that the Registration Statement will not be
“reviewed” or will not be subject to further review. HoldCo will provide a draft of the Registration Statement to the Subscriber for review at least three (3) business days in advance of the filing the Registration Statement, and
shall advise the Subscriber upon the Registration Statement being declared effective by the SEC. If the SEC prevents HoldCo from including any or all of the Shares proposed to be registered under the Registration Statement due to limitations on the
use of Rule 415 under the Securities Act for the resale of the Shares by the Holders or otherwise, HoldCo shall use its best efforts to ensure that the SEC determines that (1) the offering contemplated by the Registration Statement is a bona
fide secondary offering and not an offering “by or on behalf of the issuer” as defined in Rule 415 of the Securities Act and (2) the Subscriber is not a statutory underwriter. If HoldCo is unsuccessful in the efforts described in the
preceding sentence then (i) HoldCo shall cause such Registration Statement to register for resale such number of Shares which is equal to the maximum number of Shares as is permitted by the SEC and (ii) the Subscriber shall have an
opportunity to withdraw its Shares. In such event, the number of Shares to be registered for each selling shareholder named in the Registration Statement shall be reduced pro rata among all such selling shareholders. HoldCo agrees that HoldCo will
cause such Registration Statement or another registration statement (which may be a 

  
 8 

 
“shelf” registration statement) to remain effective until the earlier of (i) two years from the issuance of the Shares, (ii) the date on which the Subscriber ceases to hold
the Shares covered by such Registration Statement or any such other registration statement, or (iii) on the first date on which the Subscriber can sell all of its Shares under Rule 144 of the Securities Act without limitation as to the manner
of sale or the amount of such securities that may be sold. The Subscriber agrees to disclose its beneficial ownership, as determined in accordance with Rule 13d-3 of the Exchange Act, of the Shares to HoldCo
(or its successor) upon request to assist HoldCo in making the determination described above. HoldCo’s obligations to include the Shares in the Registration Statement or any such other registration statement are contingent upon the Subscriber
furnishing in writing to HoldCo such information regarding the Subscriber, the securities of HoldCo held by the Subscriber and the intended method of disposition of the Shares as shall be reasonably requested by HoldCo to effect the registration of
the Shares, and shall execute such documents in connection with such registration as HoldCo may reasonably request that are customary of a selling stockholder in similar situations; provided that, in connection therewith, the undersigned shall not
be required to enter into any lock-up or similar arrangement or otherwise be subject to any contractual restrictions with HoldCo on the ability to transfer the Shares. HoldCo may delay filing, delay
effectiveness or suspend the use of any such registration statement if it determines that (i) the financial statements included in such registration statement are required to be updated in order to comply with Regulation S-X age of financial statement requirements or (ii) in order for such registration statement to not contain a material misstatement or omission of a material fact, an amendment thereto or a supplement to the
related prospectus would be needed, or if such filing or use could materially affect a bona fide business or financing transaction of HoldCo or would require premature disclosure of information that could materially adversely affect HoldCo (each
such circumstance, a “Suspension Event”); provided, however, that HoldCo may not delay or suspend any such registration statement on more than two (2) occasions or for more than 60 consecutive calendar days, or more than 90
total calendar days, in each case during any twelve-month period. Upon receipt of any written notice from HoldCo of the happening of any Suspension Event during the period that the Registration Statement or any such other registration statement is
effective or if as a result of a Suspension Event the Registration Statement or any such other registration statement or related prospectus contains any untrue statement of a material fact or omits to state a material fact required to be stated
therein or necessary to make the statements therein, in light of the circumstances under which they were made (in the case of the related prospectus), not misleading, the Subscriber agrees that it will (i) immediately discontinue offers and
sales of the Shares under the Registration Statement or any such other registration statement until the Subscriber receives (A) (x) copies of a supplemental or amended prospectus that corrects the misstatement(s) or omission(s) referred to
above and (y) notice that any post-effective amendment has become effective or (B) notice from HoldCo that it may resume such offers and sales, and (ii) maintain the confidentiality of any information included in such written notice
delivered by HoldCo unless otherwise required by applicable law. If so directed by HoldCo, the Subscriber will deliver to HoldCo or destroy all copies of the prospectus covering the Shares in the Subscriber’s possession; provided, however, that
this obligation to deliver or destroy all copies of the prospectus covering the Shares shall not apply to (i) the extent the Subscriber is required to retain a copy of such prospectus (A) in order to comply with applicable legal,
regulatory, self-regulatory or professional requirements or (B) in accordance with a bona fide pre-existing document retention policy or (ii) copies stored electronically on archival servers as a
result of automatic data back-up. 
 HoldCo shall, if requested by Subscriber to (i) cause the
removal of the restrictive legends from any Shares while a registration statement (including the Registration Statement) covering the resale of such security is effective under the Securities Act and (ii) cause its legal counsel to deliver an
opinion, if necessary, to HoldCo’s transfer agent in connection with the removal of such restrictive legends promptly after the effectiveness date of the applicable registration statement, in each case upon the receipt of customary
representations and other documentation from the Subscriber that is necessary to establish that restrictive legends are no longer required as reasonably requested by HoldCo, its counsel or transfer agent. HoldCo agrees that following the relevant
effectiveness date and the delivery by the undersigned to HoldCo 

  
 9 

 
or the transfer agent of a certificate representing Shares issued with a restrictive legend, it will deliver or cause to be delivered to such Subscriber a certificate representing such Shares
that is free from all restrictive and other legends. Certificates for Shares subject to legend removal hereunder shall be transmitted by the transfer agent to the undersigned by crediting the account of the undersigned’s prime broker with the
Depository Trust Company System as directed by such Subscriber. HoldCo shall pay all transfer agent fees (including, without limitation, any fees required for same-day processing of any instruction letter
delivered by HoldCo and any exercise notice delivered by the undersigned), stamp taxes and other taxes and duties levied in connection with the delivery of any Shares to the undersigned other than income and capital gains taxes of the undersigned
that may be incurred in connection with the transactions contemplated hereby. The Subscriber agrees with HoldCo that it will sell any Shares pursuant to either the registration requirements of the Securities Act, including any applicable prospectus
delivery requirements, or an exemption therefrom, and that if Shares are sold pursuant to a registration statement, they will be sold in compliance with the plan of distribution set forth therein, and acknowledges that the removal of the restrictive
legend from certificates representing Shares as set forth in this Section 6 is predicated upon HoldCo’s reliance upon this understanding. 

HoldCo shall, notwithstanding any termination of this Subscription Agreement, indemnify, defend and hold harmless Subscriber (to the extent a
seller under the Registration Statement), and any of its respective officers, directors, agents, partners, members, stockholders, affiliates, managers, investment advisers and employees, and each person who controls Subscriber (within the meaning of
Section 15 of the Securities Act or Section 20 of the Exchange Act), to the fullest extent permitted by applicable law, from and against any and all
out-of-pocket losses, claims, damages, liabilities, costs (including, without limitation, reasonable external attorneys’ fees and expenses incurred in connection
with defending or investigating any such action or claim) and expenses (collectively, “Losses”), as incurred, that arise out of or are based upon any untrue or alleged untrue statement of a material fact contained in the
Registration Statement, any prospectus included in the Registration Statement or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission to
state a material fact required to be stated therein or necessary to make the statements therein (in the case of any prospectus or form of prospectus or supplement thereto, in the light of the circumstances under which they were made) not misleading,
except insofar as and to the extent, but only to the extent, that such untrue statements, alleged untrue statements, omissions or alleged omissions are based upon information regarding the Subscriber furnished in writing to HoldCo by such Subscriber
expressly for use therein or such Subscriber has omitted a material fact from such information or otherwise violated the Securities Act, the Exchange Act or any state securities law or any rule or regulation thereunder; provided, however, that the
indemnification contained in this Section 6 shall not apply to amounts paid in settlement of any Losses if such settlement is effected without the consent of HoldCo (which consent shall not be unreasonably withheld, conditioned or delayed), nor
shall HoldCo be liable for any Losses to the extent they arise out of or are based upon a violation which occurs (A) in reliance upon and in conformity with written information furnished by such Subscriber, (B) in connection with any
failure of such person to deliver or cause to be delivered a prospectus made available by HoldCo in a timely manner, (C) as a result of offers or sales effected by or on behalf of any person by means of a “free writing prospectus” (as
defined in Rule 405 under the Securities Act) that was not authorized in writing by HoldCo, or (D) in connection with any offers or sales effected by or on behalf of such Subscriber in violation of Section 6 hereof. HoldCo shall notify the
Subscriber promptly of the institution, threat or assertion of any proceeding arising from or in connection with the transactions contemplated by this Section 6 of which HoldCo is aware. Such indemnity shall remain in full force and effect
regardless of any investigation made by or on behalf of an indemnified party and shall survive the transfer of the Securities by Subscriber or any other Holder. 

  
 10 

 7. Termination. This Subscription Agreement shall terminate and be void
and of no further force and effect, and all rights and obligations of the parties hereunder shall terminate without any further liability on the part of any party in respect thereof, upon the earlier to occur of: (a) the mutual written
agreement of each of the parties hereto to terminate this Subscription Agreement; (b) such date and time as the Transaction Agreement is terminated in accordance with its terms; or (c) written notice by either party to the other party to
terminate this Subscription Agreement if the transactions contemplated by this Subscription Agreement are not consummated on or prior to December 31, 2021; provided that (i) nothing herein will relieve any party from liability for
any willful breach hereof prior to the time of termination, and each party will be entitled to any remedies at law or in equity to recover losses, liabilities or damages arising from such breach. SC Health and shall notify the Subscriber of the
termination of the Transaction Agreement promptly after the termination of such agreement and (ii) the provisions of Sections 8 through 10 of this Subscription Agreement will survive any termination of this Subscription Agreement
and continue indefinitely. 
 8. Trust Account Waiver. The Subscriber hereby represents and warrants that it has read
the Prospectus and understands that SC Health has established a trust account (the “Trust Account”) containing the proceeds of its initial public offering (the “IPO”) and the overallotment shares acquired by its
underwriters and from certain private placements occurring simultaneously with the IPO (including interest accrued from time to time thereon) for the benefit of SC Health’s public stockholders (including overallotment shares acquired by SC
Health’s underwriters, the “Public Stockholders”), and that, except as otherwise described in the Prospectus, SC Health may disburse monies from the Trust Account only: (a) to the Public Stockholders in the event they
elect to redeem their SC Health shares in connection with the consummation of SC Health’s initial business combination (as such term is used in the Prospectus, the “Business Combination”) or in connection with an extension of
its deadline to consummate a Business Combination, (b) to the Public Stockholders if SC Health fails to consummate a Business Combination within 21 months after the closing of the IPO, which is subject to extension by amendment to SC
Health’s organizational documents, (c) with respect to any interest earned on the amounts held in the Trust Account, amounts necessary to pay for any franchise and income tax obligations and up to $100,000 in dissolution expenses, or
(d) to SC Health after or concurrently with the consummation of a Business Combination. For and in consideration of SC Health entering into this Subscription Agreement, and for other good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged, the Subscriber hereby agrees on behalf of itself and its affiliates that, notwithstanding anything to the contrary in this Subscription Agreement, neither the Subscriber nor any of its affiliates do now or shall at
any time hereafter have any right, title, interest or claim of any kind in or to any monies in the Trust Account or distributions therefrom, or make any claim against the Trust Account (including any distributions therefrom), regardless of whether
such claim arises as a result of, in connection with or relating in any way to, this Subscription Agreement, the Transaction or any proposed or actual business relationship between SC Health or its Representatives, on the one hand, and the
Subscriber or its Representatives, on the other hand, or any other matter, and regardless of whether such claim arises based on contract, tort, equity or any other theory of legal liability (collectively, the “Released Claims”);
provided, however, that nothing in this Section 8 shall be deemed to limit any Subscriber’s right to distributions from the Trust Account in accordance with its rights as a Public Stockholder in respect of shares of SC
Health acquired by any means other than pursuant to this Subscription Agreement. The Subscriber on behalf of itself and its affiliates hereby irrevocably waives any Released Claims that the Subscriber or any of its affiliates may have against the
Trust Account (including any distributions therefrom) now or in the future as a result of, or arising out of, any negotiations, contracts or agreements with SC Health or its Representatives and will not seek recourse against the Trust Account
(including any distributions therefrom) for any reason whatsoever (including for an alleged breach of this Subscription Agreement or any other agreement with SC Health or its affiliates). The Subscriber agrees and acknowledges that such irrevocable
waiver is material to this Subscription Agreement and specifically relied upon by SC Health and its affiliates to induce SC Health to enter in this Subscription Agreement, and the Subscriber further intends and understands such waiver to be valid,
binding and enforceable against the Subscriber and each of its affiliates under applicable law. To the extent the Subscriber or any of its affiliates commences any action or proceeding based upon, in connection with, relating to or arising out of
any matter 

  
 11 

 
relating to SC Health or its Representatives, which proceeding seeks, in whole or in part, monetary relief against SC Health or its Representatives, the Subscriber hereby acknowledges and agrees
that the Subscriber’s and its affiliates’ sole remedy shall be against funds held outside of the Trust Account and that such claim shall not permit the Subscriber or its affiliates (or any person claiming on any of their behalves or in
lieu of any of them) to have any claim against the Trust Account (including any distributions therefrom) or any amounts contained therein. In the event the Subscriber or any of its affiliates commences any action or proceeding based upon, in
connection with, relating to or arising out of any matter relating to SC Health or its Representatives, which proceeding seeks, in whole or in part, relief against the Trust Account (including any distributions therefrom) or against SC Health or the
Public Stockholders, whether in the form of money damages or injunctive relief, SC Health and its Representatives, as applicable, shall be entitled to recover from the Subscriber and its affiliates the associated legal fees and costs in connection
with any such action in the event SC Health or its Representatives, as applicable, prevails in such action or proceeding. For purposes of this Subscription Agreement, “Representatives” with respect to any person shall mean such
person’s affiliates and its and its affiliate’s respective directors, officers, employees, consultants, advisors, agents and other representatives. Notwithstanding anything to the contrary contained in this Subscription Agreement, the
provisions of this Section 8 shall survive the Closing or any termination of this Subscription Agreement and last indefinitely. 

9. Miscellaneous. 

(a) SC Health shall, no later than 9:00 a.m., New York City time, on the first business day immediately following the date of this Subscription
Agreement, issue one or more press releases or file with the SEC a Current Report on Form 8-K (collectively, the “Signing 8-K”) disclosing all material
terms of the transactions contemplated hereby, the Transaction and any other material, nonpublic information that SC Health or any of its officers, directors, employees or agents (including the Placement Agents) has provided to the undersigned at
any time prior to the filing of the Signing 8-K. From and after the issuance of the Signing 8-K, the undersigned shall not be in possession of any material, non-public information received from SC Health or any of its officers, directors, employees or agents (including the Placement Agents) and the Subscriber shall no longer be subject to any confidentiality or similar
obligations under any current agreement, whether written or oral with SC Health, the Placement Agents, or any of their respective affiliates. Except with the express written consent of the Subscriber and unless prior thereto the Subscriber shall
have executed a written agreement regarding the confidentiality and use of such information, neither SC Health nor Holdco shall, and shall cause its officers, directors, employees and agents, not to, provide Subscriber with any material, non-public information regarding SC Health, Holdco or the Transaction from and after the filing of the Signing 8-K. 

(b) Neither this Subscription Agreement nor any rights that may accrue to the Subscriber hereunder (other than the Shares acquired hereunder,
if any, subject to applicable securities laws) may be transferred or assigned by the Subscriber without the prior written consent of SC Health and HoldCo, and any purported transfer or assignment without such consent shall be null and void ab
initio. 
 (c) HoldCo and SC Health may request from the Subscriber such additional information as SC Health and/or HoldCo may deem necessary
to evaluate the eligibility of the Subscriber to acquire the Shares, and the Subscriber shall provide such information to SC Health and HoldCo upon such request provided that SC Health and HoldCo keep any such information so provided confidential,
it being understood by the Subscriber that HoldCo and SC Health may without any liability hereunder reject the Subscriber’s subscription prior to the Closing Date in the event the Subscriber fails to provide such additional information
requested by SC Health and HoldCo to evaluate the Subscriber’s eligibility or SC Health and HoldCo determines that the Subscriber is not eligible. 

  
 12 

 (d) The Subscriber acknowledges that SC Health, HoldCo, the Placement Agent, the Target and
others will rely on the acknowledgments, understandings, agreements, representations and warranties of the Subscriber contained in this Subscription Agreement. Prior to the Closing, the Subscriber agrees to promptly notify SC Health and HoldCo if
any of the acknowledgments, understandings, agreements, representations and warranties set forth herein are no longer accurate. The Subscriber agrees that the purchase by the Subscriber of Shares from HoldCo will constitute a reaffirmation of the
acknowledgments, understandings, agreements, representations and warranties herein (as modified by any such notice) by the Subscriber as of the time of such purchase. The Subscriber acknowledges and agrees that each of the Placement Agents and the
Target and their respective affiliates is a third-party beneficiary of the representations, warranties and covenants of the Subscriber contained in Section 5 of this Subscription Agreement, and that the Target is otherwise an express third
party beneficiary of this Subscription Agreement, entitled to enforce the terms hereof against Subscriber as if it were an original party hereto. Except as expressly set forth herein, this Subscription Agreement shall not confer any rights or
remedies upon any person other than the parties hereto, and their respective successor and assigns. 
 (e) Each of SC Health and HoldCo is
entitled to rely upon this Subscription Agreement and is irrevocably authorized to produce this Subscription Agreement or a copy hereof to any interested party in any administrative or legal proceeding or official inquiry with respect to the matters
covered hereby to the extent required by law or regulatory bodies. Neither party shall issue any press release or make any other similar public statement with respect to the transactions contemplated hereby without the prior written consent of SC
Health and HoldCo (such consent not to be unreasonably withheld or delayed). 
 (f) All the agreements, representations and warranties made
by each party hereto in this Subscription Agreement shall survive the Closing. 
 (g) This Subscription Agreement may not be amended,
modified, waived or terminated except by an instrument in writing, signed by the party against whom enforcement of such modification, waiver, or termination is sought. 

(h) This Subscription Agreement constitutes the entire agreement, and supersedes all other prior agreements, understandings, representations
and warranties, both written and oral, among the parties, with respect to the subject matter hereof (other than any confidentiality agreement entered into by SC Health and/or HoldCo and the Subscriber in connection with the Offering). 

(i) This Subscription Agreement shall be binding upon, and inure to the benefit of the parties hereto and their heirs, executors,
administrators, successors, legal representatives, and permitted assigns, and the agreements, representations, warranties, covenants and acknowledgments contained herein shall be deemed to be made by, and be binding upon, such heirs, executors,
administrators, successors, legal representatives and permitted assigns. 
 (j) If any provision of this Subscription Agreement shall be
invalid, illegal or unenforceable, the validity, legality or enforceability of the remaining provisions of this Subscription Agreement shall not in any way be affected or impaired thereby and shall continue in full force and effect. 

(k) This Subscription Agreement may be executed in one or more counterparts (including by facsimile or electronic mail or in .pdf) and by
different parties in separate counterparts, with the same effect as if all parties hereto had signed the same document. All counterparts so executed and delivered shall be construed together and shall constitute one and the same agreement. 

  
 13 

 (l) The parties hereto agree that irreparable damage would occur in the event that any of
the provisions of this Subscription Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to seek an injunction or injunctions to prevent breaches
of this Subscription Agreement and to enforce specifically the terms and provisions of this Subscription Agreement, this being in addition to any other remedy to which such party is entitled at law, in equity, in contract, in tort or otherwise. 

(m) THIS SUBSCRIPTION AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD
TO THE PRINCIPLES OF CONFLICTS OF LAWS THAT WOULD OTHERWISE REQUIRE THE APPLICATION OF THE LAW OF ANY OTHER STATE. EACH PARTY HERETO HEREBY WAIVES ANY RIGHT TO A JURY TRIAL IN CONNECTION WITH ANY LITIGATION PURSUANT TO THIS SUBSCRIPTION AGREEMENT
AND THE TRANSACTIONS CONTEMPLATED HEREBY. 
 (n) All notices, consents, waivers and other communications hereunder shall be in writing
and shall be deemed to have been duly given (i) when delivered in person, (ii) when delivered by facsimile or email, with affirmative confirmation of receipt, (iii) one business day after being sent, if sent by reputable,
internationally recognized overnight courier service or (iv) three (3) business days after being mailed, if sent by registered or certified mail, prepaid and return receipt requested, in each case to the applicable party at the following
addresses (or at such other address for a party as shall be specified by like notice): 
  

			
	 If to SC Health, to:
  

SC Health Corporation 
108 Robinson Road #10-00

Singapore 068900 
Attention: Jeri Kwerk 

AJ Coloma 
Eric Teo 
Terence Fong 
Aaron Wee 
Clement Chen 

Email: jeri.kwek@sincapital.com 

aj.coloma@sincapital.com 
eric.teo@sincapital.com 
terence.fong@sincapital.com 
aaron.wee@sincapital.com

Clement.Chen@sincapital.com
	  	 with copies (which shall not constitute notice) to:
  

Ropes & Gray LLP 
1211 Avenue of the Americas 
New York, NY 10036 
Attn: Paul Tropp, Chris Capuzzi and Carl P. Marcellino 
Email:
carl.marcellino@ropesgray.com 
Telephone No.: (212) 841-0623
  

and
  

Merrill Lynch (Singapore) Pte. Ltd.
 50 Collyer Quay, #14-01
 OUE Bayfront

Singapore 049321
 Attention: Clemente Antonio Puno

Telephone No.: +65 6678 0157 
Email: antonio.puno@bofa.com
  

Cowen and Company, LLC.
 599 Lexington Avenue, 25th Floor

New York, NY 10022
 Attention: Vinni Trehan 
Email:
vinni.trehan@cowen.com

		
	 If to HoldCo, to:
  

Rockley Photonics Holdings Limited 
3rd Floor 
1 Ashley Road 
Altrincham, Cheshire 
United Kingdom, WA14 2DT 
Attention: Dr. Andrew Rickman

Email:andrew.rickman@rockleyphotonics.com
	  	 with copies (which shall not constitute notice) to:
  

Pillsbury Winthrop Shaw Pittman LLP 
31 West 52nd Street 
New York, New York 10019

 
 Attention: James Masetti and Jarrod Murphy

Email:jim.masetti@pillsburylaw.com 
jarrod.murphy@pillsburylaw.com

  
 14 

			
	Notice to the Subscriber shall be given to the address underneath the Subscriber’s name on the signature page hereto.

 (o) The headings set forth in this Subscription Agreement are for convenience of reference only and shall not
be used in interpreting this Subscription Agreement. In this Subscription Agreement, unless the context otherwise requires: (i) whenever required by the context, any pronoun used in this Subscription Agreement shall include the corresponding
masculine, feminine or neuter forms, and the singular form of nouns, pronouns and verbs shall include the plural and vice versa; (ii) “including” (and with correlative meaning “include”) means including without limiting the
generality of any description preceding or succeeding such term and shall be deemed in each case to be followed by the words “without limitation”; and (iii) the words “herein”, “hereto” and “hereby” and
other words of similar import in this Subscription Agreement shall be deemed in each case to refer to this Subscription Agreement as a whole and not to any particular portion of this Subscription Agreement. As used in this Subscription Agreement,
the term: (x) “business day” shall mean any day other than a Saturday, Sunday or a legal holiday on which commercial banking institutions in New York, New York (or as such term is used in Section 6 hereof, Washington, D.C.) are
authorized to close for business (excluding as a result of “stay at home”, “shelter-in-place”,
“non-essential employee” or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds
transfer systems, including for wire transfers, of commercially banking institutions in New York, New York are generally open for use by customers on such day); (y) “person” shall refer to any individual, corporation, partnership, trust,
limited liability company or other entity or association, including any governmental or regulatory body, whether acting in an individual, fiduciary or any other capacity; and (z) “affiliate” shall mean, with respect to any specified
person, any other person or group of persons acting together that, directly or indirectly, through one or more intermediaries controls, is controlled by or is under common control with such specified person (where the term “control” (and
any correlative terms) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of such person, whether through the ownership of voting securities, by contract or otherwise). For the
avoidance of doubt, any reference in this Subscription Agreement to an affiliate of the SC Health will include SC Health’s sponsor, SC Health Holdings Limited. 

(p) At Closing, the parties hereto shall execute and deliver such additional documents and take such additional actions as the parties may
reasonably deem practical and necessary in order to consummate the Offering as contemplated by this Subscription Agreement. 
 10.
Non-Reliance and Exculpation. The Subscriber acknowledges that it is not relying upon, and has not relied upon, any statement, representation or warranty made by any person other than the
statements, representations and warranties contained in this Subscription Agreement in making its investment or decision to invest in HoldCo. The Subscriber agrees that neither (i) any other purchaser pursuant to other subscription agreements
entered into in connection with the Offering (including the controlling persons, members, officers, directors, partners, agents, or employees of any such other purchaser) nor (ii) each Placement Agent, each of their respective affiliates or any
of their respective affiliates’ respective control persons, officers, directors or employees, shall be liable to the Subscriber pursuant to this Subscription Agreement, the negotiation hereof or thereof or its subject matter, or the
transactions contemplated hereby or thereby, including, without limitation, for any action heretofore or hereafter taken or omitted to be taken by any of them in connection with the purchase of the Shares or with respect to any claim (whether in
tort, contract or otherwise) for breach of this Subscription Agreement or in respect of any written or oral representations made or alleged to be made in connection herewith, as expressly provided herein, or for any actual or alleged inaccuracies,
misstatements or omissions with respect to any information or materials of any kind furnished. 
 {SIGNATURE PAGES FOLLOW} 

  
 15 

 IN WITNESS WHEREOF, the parties hereto have caused this Subscription Agreement to be duly
executed by their respective authorized signatories as of the date first indicated above. 
  

			
	SC HEALTH CORPORATION
		
	By:	 	
                     
   

		 	Name:
		 	Title:

 {Signature Page to Subscription Agreement} 

 
			
	ROCKLEY PHOTONICS HOLDINGS LIMITED
		
	By:	 	
                    

		 	Name:
		 	Title:

 {Signature Page to Subscription Agreement} 

 {SUBSCRIBER SIGNATURE PAGE TO THE SUBSCRIPTION AGREEMENT} 

IN WITNESS WHEREOF, the undersigned has caused this Subscription Agreement to be duly executed by its authorized signatory as of the date
first indicated above. 
 Name(s) of
Subscriber:                                       
                                         
                                         
                                         
   
 Signature of Authorized Signatory of
Subscriber:                                      
                                         
                                         
    
 Name of Authorized
Signatory:                                       
                                         
                                         
                                

Title of Authorized
Signatory:                                       
                                         
                                         
                                  

Address for Notice to Subscriber: 

                          
                                         
                                         
                                         
                                         
             

                          
                                         
                                         
                                         
                                         
             

                          
                                         
                                         
                                         
                                         
             

Attention:                     
                                         
                                         
                                         
                                   

Email:                      
                                         
                                         
                                         
                                        

Facsimile
No.:                                        
                                         
                                         
                                         
         
 Telephone
No.:                                        
                                         
                                         
                                         
        
 Address for Delivery of Shares to Subscriber (if not same as address for notice): 

                          
                                         
                                         
                                         
                                         
             

                          
                                         
                                         
                                         
                                         
             

                          
                                         
                                         
                                         
                                         
             
 Subscription Amount:
$                                         
                
 Number of
Shares:                                       
                          

EIN
Number:                                        
                                   

 SCHEDULE I 

ELIGIBILITY REPRESENTATIONS OF SUBSCRIBER 
  

					
	A.	  	NOT A U.S. PERSON (please check the applicable subparagraphs)
		
		  	☐ I am not a “U.S. Person” (as defined in Regulation S under the Securities Act of 1933, as amended (the “Securities Act”)) and I am not acquiring Shares for the account or benefit
of any U.S. Person.
	
	*** OR ***
		
	B.	  	QUALIFIED INSTITUTIONAL BUYER STATUS
			
		  		  	(Please check the applicable subparagraphs):
			
		  	1.	  	 ☐   We are a “qualified institutional buyer” (as defined in Rule
144A under the Securities Act) (a “QIB”) and have marked and initialed the appropriate box on the following pages indicating the provision under which we qualify as a QIB.

			
		  	2.	  	 ☐   We are subscribing for the Shares as a fiduciary or agent for one or
more investor accounts, and each owner of such account is a QIB.

	
	*** OR ***
		
	C.	  	INSTITUTIONAL ACCREDITED INVESTOR STATUS (Please check the applicable subparagraphs):
			
		  	1.	  	 ☐   We are an “accredited investor” (within the meaning of Rule
501(a)(1), (2), (3), (7), or (8) under the Securities Act) and have marked and initialed the appropriate box on the following pages indicating the provision under which we qualify as an “accredited investor.”

			
		  	2.	  	 ☐   We are not a natural person.

	
	*** AND ***
		
	D.	  	AFFILIATE STATUS (Please check the applicable box)
		
		  	SUBSCRIBER:
		
		  	 ☐   is:

		
		  	 ☐   is not:

		
		  	an “affiliate” (as defined in Rule 144 under the Securities Act) of the Issuer or acting on behalf of an affiliate of the Issuer.

  
 A-1 

 This page should be completed by Subscriber 

and constitutes a part of the Subscription Agreement. 

The Subscriber is a “qualified institutional buyer” (within the meaning of Rule 144A under the Securities Act) if it is an entity that meets any one
of the following categories at the time of the sale of securities to the Subscriber (Please check the applicable subparagraphs): 
 ☐ The Subscriber
is an entity that, acting for its own account or the accounts of other qualified institutional buyers, in the aggregate owns and invests on a discretionary basis at least $100 million in securities of issuers that are not affiliated with the
Subscriber and: 
 ☐ is an insurance company as defined in section 2(a)(13) of the Securities Act; 

☐ is an investment company registered under the Investment Company Act of 1940, as amended (the “Investment Company
Act”), or any business development company as defined in section 2(a)(48) of the Securities Act; 
 ☐ is a Small Business
Investment Company licensed by the US Small Business Administration under section 301(c) or (d) of the Small Business Investment Act of 1958, as amended (“Small Business Investment Act”) or any Rural Business Investment Company
as defined in section 384A of the Consolidated Farm and Rural Development Act; 
 ☐ is a plan established and maintained by a state,
its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees; 

☐ is an employee benefit plan within the meaning of Title I of the Employee Retirement Income Security Act of 1974, as amended
(“ERISA”); 
 ☐ is a trust fund whose trustee is a bank or trust company and whose participants are exclusively
(a) plans established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, of (b) employee benefit plan within the meaning of
Title I of the ERISA, except, in each case, trust funds that include as participants individual retirement accounts or H.R. 10 plans; 

☐ is a business development company as defined in section 202(a)(22) of the Investment Advisers Act of 1940, as amended (the
“Investment Advisers Act”); 
 ☐ is an organization described in section 501(c)(3) of the Internal Revenue Code of
1986, as amended (the “Internal Revenue Code”), corporation (other than a bank as defined in section 3(a)(2) of the Securities Act, a savings and loan association or other institution referenced in section 3(a)(5)(A) of the
Securities Act, or a foreign bank or savings and loan association or equivalent institution), partnership, limited liability company, or Massachusetts or similar business trust; or 

  
 A-2 

 ☐ is an investment adviser registered under the Investment Advisers Act; 

☐ The Subscriber is a dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), acting for its own account or the accounts of other qualified institutional buyers, that in the aggregate owns and invests on a discretionary basis at least $10 million of securities of issuers that are not affiliated with the
Subscriber; 
 ☐ The Subscriber is a dealer registered pursuant to Section 15 of the Exchange Act acting in a riskless principal transaction on
behalf of a qualified institutional buyer; 
 ☐ The Subscriber is an investment company registered under the Investment Company Act, acting for its own
account or for the accounts of other qualified institutional buyers, that is part of a family of investment companies1 which own in the aggregate at least $100 million in securities of
issuers, other than issuers that are affiliated with Subscriber or are part of such family of investment companies; 
 ☐ The Subscriber is an entity,
all of the equity owners of which are qualified institutional buyers, acting for its own account or the accounts of other qualified institutional buyers; or 

☐ The Subscriber is a bank as defined in section 3(a)(2) of the Securities Act, or any savings and loan association or other institution as defined in
section 3(a)(5)(A) of the Securities Act, or any foreign bank or savings and loan association or equivalent institution, acting for its own account or the accounts of other qualified institutional buyers, that in the aggregate owns and invests on a
discretionary basis at least $100 million in securities of issuers that are not affiliated with the Subscriber and that has an audited net worth of at least $25 million as demonstrated in its latest annual financial statements, as of a
date not more than 16 months preceding the date of sale of securities in the case of a US bank or savings and loan association, and not more than 18 months preceding the date of sale of securities for a foreign bank or savings and loan association
or equivalent institution. 
  

	1 	 “Family of investment companies” means any two or more investment companies registered under
the Investment Company Act, except for a unit investment trust whose assets consist solely of shares of one or more registered investment companies, that have the same investment adviser (or, in the case of unit investment trusts, the same
depositor); provided that, (a) each series of a series company (as defined in Rule 18f-2 under the Investment Company Act) shall be deemed to be a separate investment company and (b) investment
companies shall be deemed to have the same adviser (or depositor) if their advisers (or depositors) are majority-owned subsidiaries of the same parent, or if one investment company’s adviser (or depositor) is a majority-owned subsidiary of the
other investment company’s adviser (or depositor). 

  
 A-3 

 Rule 501(a) under the Securities Act, in relevant part, states that an “accredited investor” shall
mean any person who comes within any of the below listed categories, or who the issuer reasonably believes comes within any of the below listed categories, at the time of the sale of the securities to that person. Subscriber has indicated, by
marking and initialing the appropriate box(es) below, the provision(s) below which apply to Subscriber and under which Subscriber accordingly qualifies as an “accredited investor.” 

 

	☐	 Any bank as defined in section 3(a)(2) of the Securities Act, or any savings and loan association or other
institution as defined in section 3(a)(5)(A) of the Securities Act whether acting in its individual or fiduciary capacity; 

  

	☐	 Any broker or dealer registered pursuant to section 15 of the Exchange Act; 

 

	☐	 Any investment adviser registered pursuant to section 203 of the Investment Advisers Act or registered pursuant
to the laws of a state; 

  

	☐	 Any investment adviser relying on the exemption from registering with the SEC under section 203(l) or
(m) of the Investment Advisers Act; 

  

	☐	 Any insurance company as defined in section 2(a)(13) of the Securities Act; 

 

	☐	 Any investment company registered under the Investment Company Act or a business development company as defined
in section 2(a)(48) of the Investment Company Act; 

  

	☐	 Any Small Business Investment Company licensed by the U.S. Small Business Administration under section 301(c)
or (d) of the Small Business Investment Act; 

  

	☐	 Any Rural Business Investment Company as defined in section 384A of the Consolidated Farm and Rural Development
Act; 

  

	☐	 Any plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of
a state or its political subdivisions, for the benefit of its employees, if such plan has total assets in excess of $5,000,000; 

  

	☐	 Any employee benefit plan within the meaning of Title I of the ERISA, if (i) the investment decision is
made by a plan fiduciary, as defined in section 3(21) of ERISA, which is either a bank, a savings and loan association, an insurance company, or a registered investment adviser, (ii) the employee benefit plan has total assets in excess of
$5,000,000 or, (iii) such plan is a self-directed plan, with investment decisions made solely by persons that are “accredited investors”; 

  

	☐	 Any private business development company as defined in section 202(a)(22) of the Investment Advisers Act;

  

	☐	 Any (i) corporation, limited liability company or partnership, (ii) Massachusetts or similar business
trust, or (iii) organization described in section 501(c)(3) of the Internal Revenue Code, in each case that was not formed for the specific purpose of acquiring the securities offered and that has total assets in excess of $5,000,000;

  
 A-4 

	☐	 Any trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the
securities offered, whose purchase is directed by a sophisticated person as described in Section 230.506(b)(2)(ii) of Regulation D under the Securities Act; or 

 

	☐	 Any entity in which all of the equity owners are “accredited investors.” 

  
 A-5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}]]